SUMMARY Infrared television pupillometry was performed on 34 insulin-treated diabetic patients and 55 healthy subjects. Sixteen of the diabetic patients had pupils that failed to dilate normally in darkness. The occurrence of a small pupil was associated with cardiac vagal dysfunction and somatic sensory loss. The small pupil was found to be supersensitive to the mydriatic effect of topical 2% phenylephrine but normally sensitive to 0 5% hydroxyamphetamine eyedrops. It is concluded that the failure of the pupil to dilate in darkness in some diabetic patients is due to neuropathy of the sympathetic innervation.
Diabetics with neuropathy often have abnormally small pupils that fail to dilate normally in darkness.' One possible cause is neuropathy of the sympathetic innervation of the dilator pupillae. This explanation is supported by the fact that the small pupil commonly occurs in association with autonomic dysfunction in other organs.' However, the iris of such patients is often damaged, with lesions of the smooth muscles, connective tissue, and blood vessels.23 This suggests an alternative explanation of the small pupil, namely, that local damage to the iris limits its mobility.
These alternative aetiologies have been investigated by studying the pupillary responses to topical sympathomimetic amines in diabetic patients with and without small pupils. Experience from studies on Horner's pupils has shown that denervation enhances the. response to phenylephrine, a directly acting sympathomimetic amine, which dilates the pupil by activation of the a-adrenoceptors on the dilator pupillae.4 By contrast the response to hydroxyamphetamine, an indirectly acting sympathomimetic which works by releasing transmitter (noradrenaline) from the sympathetic nerve terminals, is variably affected according to the site of the lesion.56 Local iris damage on the other hand can be expected to reduce the response to any dilating agent. Healthy subjects were also studied to define the normal mydriatic response to phenylephrine and hydroxyamphetamine. where y=mydriatic response in mm and x=age in years.
The age dependence of the response to these drugs was taken into account in assessing the results in the diabetic patients, illustrated in Figs. 4 and 5. These show that the small pupil in patients with diabetic neuropathy was associated with an exaggerated response to phenylephrine and a normal response to hydroxyamphetamine. The mean mydriatic response for the 4 groups is shown in Table 2 . Only in the 2 groups with significantly reduced pupil diameters was the response to phenylephrine significantly greater than normal.
Twenty of the diabetic patients, from all 4 groups, had repeat pupillary measurements performed to assess their reliability. The darkness pupil diameter was remarkably constant, with a coefficient of Fig. 4 The mydriatic response to phenylephrine in diabetic subjects. The responses are expressed as deviations from the normalfor age, as in Table 1 . The normal range is indicated by the horizontal bars. Clearly the response tophenylephrine was enhanced in diabetics with small pupils.
variation of only 6%. The coefficients for the mydriatic responses were higher: 23% for phenylephrine and 13% for hydroxyamphetamine.
Discussion
These results have shown that the small pupil in diabetic patients is supersensitive to phenylephrine. Enhanced pressor responses to intravenous phenylephrine have also been reported. " This supersensitivity, which is also found in Homer's pupils,"6 is evidence in favour of a neuropathic rather than a myopathic aetiology in the miotic pupil of diabetes. Supersensitivity to agents which mimic the action of the normal transmitter occurs with pre-and postganglionic lesions in sympathetic pupillary denervation.5612 It is likely to be due to an increased activity of receptors on the muscle cell surface, although the precise nature of this increase has not been established in smooth muscle. 3 It is unlikely to be due to a failure of the neuronal uptake mechanism, as suggested by Korczyn, 4 since phenylephrine has a negligible affinity for this process-5% that of noradrenaline. '5 In contrast to the phenylephrine results the There are a number of similarities between senile miosis and diabetic miosis. In comparison with that of healthy young people the pupil in both groups fails to dilate in darkness and is differentially more sensitive to phenylephrine than to hydroxyamphetamine. The action of cocaine is reduced in the elderly pupil,'8 which suggests that a reduction ofsympathetic activity occurs with age due to a degenerative process that is accelerated in diabetes.
It is a common clinical impression that the pupil in patients with diabetic neuropathy is difficult to dilate for fundal inspection. The agents used are most commonly atropinic agents such as homatropine, cyclopentolate, and tropicamide. These normally work by paralysing the parasympathetic constrictor drive, allowing the sympathetic input to the dilator to dominate. The loss of sympathetic tone in patients with diabetic neuropathy would thus limit the usefulness of the anticholinergic njydriatics. Addition of a directly acting sympathomimetic, to which the pupil is supersensitive, may well improve the mydriasis.
The purpose of the present investigation was to differentiate between neuropathy and myopathy as causes of the small pupil, since disorders of both types occur in diabetes.2 The same problem of interpretation occurs with all the conventional autonomic function tests, usually cardiovascular, that depend on measuring the activity of the end organ rather than the activity of the nerve. The present finding that abnormal pupillary dilatation in darkness is indeed due to neuropathy validates the measurement of resting pupil size as a diagnostic test of diabetic autonomic neuropathy.
Sympathetic neuropathy of the pupillary innervation was associated with cardiac vagal and somatic sensory dysfunction. These neuropathic signs were more common in patients with long duration and poor control of their disease. This confirms the findings of Pirart'9 and others that the degree and duration of chronic hyperglycaemia are important risk factors in the development of diabetic complications.
